flow semaglutide FLOW: Scores Big in Diabetic Patients With CKD Long-term kidney outcomes of semaglutide

This matters with GLP-1 treatment because dosing, nausea management, hydration, protein intake, and long-term planning all affect the experience

After propensity score matching the GLP-1 cohort (n=45,704) included 35,753 (78.2%) women and 7,852 (17.2%) men with a mean age of 61.1, while the OWLD cohort (n=45,704) included 35,732 (78.2%) women and 7,815 (17.1%) men with a mean age of 61.0

December 2025: On December 15, 2025, the Judicial Panel on Multidistrict Litigation entered an order approving the creation of an MDL to house federal vision loss claims for Wegovy and other GLP-1 drugs

The bottom line re GLP-1s GLP-1 is a hormone that helps control blood sugar and appetite and is now being studied for its potential to slow aging and extend healthy years of life

Moreover, the degree and trajectory of weight loss may have differed substantially between semaglutide users and controls, particularly if weight loss in the control group was achieved through lifestyle-related approaches rather than pharmacologic treatment, but these differences could not be measured within TriNetX